Ubrogepant clinical trials
Ubrogepant is named as an intervention in 4 current clinical trials in our USA register. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is AbbVie. The most-studied condition is Migraine.
Where Ubrogepant is approved
All regulators →Of the three regulators tracked here, the first to approve Ubrogepant was the US, on 23 Dec 2019. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Ubrogepant patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Ubrogepant, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 16 listed patents; the last listed expires 22 Dec 2041 (US 11717515).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Ubrogepant
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Ubrogepant works
All drug targets →- Calcitonin gene-related peptide type 1 receptor antagonist AntagonistTarget: CALCRL calcitonin receptor like receptor✓ In ChEMBL and the Guide to Pharmacology
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2364638, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10176, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Ubrogepant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Ubrogepant
- ChEMBL
- CHEMBL2364638
- DrugBank
- DB15328
- PubChem CID
- 68748835
- CAS number
- 1374248-77-7
- FDA UNII
- AD0O8X2QJR
- Wikidata
- Q27273878
- Wikipedia
- Ubrogepant
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Ubrogepant
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302 · Migraine
|
Phase 3 | Recruiting | AbbVie | USA |
|
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
NCT05127954 · Migraine
|
Phase 3 | By invitation | AbbVie | USA |
|
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775 · Migraine
|
Phase 3 | Active, closed | AbbVie | USA |
|
Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
NCT07680686 · Healthy Volunteer
|
Phase 1 | Active, closed | AbbVie | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Ubrogepant
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 4 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Ubrogepant trials
How many clinical trials are testing Ubrogepant?
4 current trials in our USA register name Ubrogepant as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Ubrogepant trials recruiting patients?
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ubrogepant clinical trials?
The lead sponsor is AbbVie. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ubrogepant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ubrogepant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ubrogepant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.